View More View Less
  • 1 Institute of Nuclear Chemistry and Technology ul. Dorodna 16 03-195 Warsaw Poland
Restricted access

Abstract  

105Rh[1,5,9,13-tetrathiacyclohexadecane-3,11-diol] is a promising drug precursor for targeted radiotherapy. Nevertheless, the axial position of chloride ions in the complex structure and their weak binding to rhodium centre, due to HSAB concept, make such a complex subject to modifying action of certain sulphuric ligands, like human plasma thiol antioxidants: glutathione and cysteine. Experiments were performed with both radioactive 105Rh and inactive rhodium. The complexation of rhodium with 1,5,9,13-tetrathiacyclohexadecane-3,11-diol (16S4diol) resulted in three distinct peaks seen on UV, radiometric and MS chromatograms. The substitution of chlorides was noted in over 80% of 105[Rh(16S4diol)Cl2]+ units after incubation with glutathione, and less than 10% of complex units after incubation with cysteine (24 h, 37 °C). Reaction of 105[Rh(16S4diol)Cl2]+ with 1,8-octandithiol and 1,9-nonandithiol resulted in disappearance of the complex peak and occurrence of two new peaks. Product of RhCl3 and 16S4diol reaction is a mixture of three distinct forms having different number of chlorine atoms. Our in vitro experiments suggest that the substitution of axial chlorides with glutathione and cysteine might also occur in vivo in human plasma. Glutathione shows higher reactivity than cysteine in replacement reaction. Axial positions in precursor might be effectively blocked by 1,8-octandithiol and 1,9-nonandithiol.

Manuscript Submission: HERE

  • Impact Factor (2019): 1.137
  • Scimago Journal Rank (2019): 0.360
  • SJR Hirsch-Index (2019): 65
  • SJR Quartile Score (2019): Q3 Analytical Chemistry
  • SJR Quartile Score (2019): Q3 Health, Toxicology and Mutagenesis
  • SJR Quartile Score (2019): Q2 Nuclear Energy and Engineering
  • SJR Quartile Score (2019): Q3 Pollution
  • SJR Quartile Score (2019): Q3 Public Health, Environmental and Occupational Health
  • SJR Quartile Score (2019): Q3 Radiology, Nuclear Medicine and Imaging
  • SJR Quartile Score (2019): Q3 Spectroscopy
  • Impact Factor (2018): 1.186
  • Scimago Journal Rank (2018): 0.408
  • SJR Hirsch-Index (2018): 60
  • SJR Quartile Score (2018): Q2 Nuclear Energy and Engineering
  • SJR Quartile Score (2018): Q2 Pollution

For subscription options, please visit the website of Springer Nature.

Journal of Radionalytical and Nuclear Chemistry
Language English
Size A4
Year of
Foundation
1968
Volumes
per Year
4
Issues
per Year
12
Founder Akadémiai Kiadó
Founder's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Publisher Akadémiai Kiadó
Springer Nature Switzerland AG
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
CH-6330 Cham, Switzerland Gewerbestrasse 11.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 0236-5731 (Print)
ISSN 1588-2780 (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
May 2021 0 0 0
Jun 2021 0 0 0
Jul 2021 1 0 0
Aug 2021 0 0 0
Sep 2021 0 0 0
Oct 2021 0 0 0
Nov 2021 0 0 0